AU2003219574A1 - Controlled release formulation comprising benzimidazole derivatives or pharmaceutically acceptable salts thereof with increased stability and method for preparing the same - Google Patents

Controlled release formulation comprising benzimidazole derivatives or pharmaceutically acceptable salts thereof with increased stability and method for preparing the same

Info

Publication number
AU2003219574A1
AU2003219574A1 AU2003219574A AU2003219574A AU2003219574A1 AU 2003219574 A1 AU2003219574 A1 AU 2003219574A1 AU 2003219574 A AU2003219574 A AU 2003219574A AU 2003219574 A AU2003219574 A AU 2003219574A AU 2003219574 A1 AU2003219574 A1 AU 2003219574A1
Authority
AU
Australia
Prior art keywords
preparing
pharmaceutically acceptable
acceptable salts
same
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003219574A
Inventor
Sung Joo Hwang
Ung Kil Jee
Yong Jin Kwon
Young Girl Moon
Jin Kyu Park
Kyung Lae Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centurion Inc
Original Assignee
Centurion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centurion Inc filed Critical Centurion Inc
Publication of AU2003219574A1 publication Critical patent/AU2003219574A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2003219574A 2002-12-30 2003-04-02 Controlled release formulation comprising benzimidazole derivatives or pharmaceutically acceptable salts thereof with increased stability and method for preparing the same Abandoned AU2003219574A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020020087300A KR100592511B1 (en) 2002-12-30 2002-12-30 Release Controlled type Formulation Comprising Benzimidazole Derivatives and There Pharmaceutically Acceptable Salt with Increased Stability and Manufacturing Method thereof
KR10-2002-0087300 2002-12-30
PCT/KR2003/000659 WO2004058257A1 (en) 2002-12-30 2003-04-02 Controlled release formulation comprising benzimidazole derivatives or pharmaceutically acceptable salts thereof with increased stability and method for preparing the same

Publications (1)

Publication Number Publication Date
AU2003219574A1 true AU2003219574A1 (en) 2004-07-22

Family

ID=32677817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003219574A Abandoned AU2003219574A1 (en) 2002-12-30 2003-04-02 Controlled release formulation comprising benzimidazole derivatives or pharmaceutically acceptable salts thereof with increased stability and method for preparing the same

Country Status (3)

Country Link
KR (1) KR100592511B1 (en)
AU (1) AU2003219574A1 (en)
WO (1) WO2004058257A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US8519120B2 (en) 2006-08-08 2013-08-27 Shin-Etsu Chemical Co., Ltd. Methods for producing a low-substituted hydroxypropylcellulose powder
US8343547B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
CN102336788B (en) * 2011-06-29 2014-08-27 涂家生 Glucosamine double salt for proton pump inhibitor
CN104784206B (en) * 2015-03-16 2017-07-14 浙江圣博康药业有限公司 A kind of Muhivitamin Formula With Minerals dispersible tablet
KR102146724B1 (en) * 2017-12-22 2020-08-21 (주)휴온스 Pharmaceutical formulation comprising benzimidazole and preparation method thereof
US20220211603A1 (en) * 2019-05-22 2022-07-07 3M Innovative Properties Company Oral Compositions And Methods Of Use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
PT1021171E (en) * 1997-10-09 2003-10-31 Dexcel Pharma Technologies Ltd SYSTEM OF ADMINISTRATION OF DRUGS IN THE GASTROINTESTINAL TRACT OF TOTAL PROLONGED LIBERATION

Also Published As

Publication number Publication date
KR20040060500A (en) 2004-07-06
WO2004058257A1 (en) 2004-07-15
KR100592511B1 (en) 2006-07-03

Similar Documents

Publication Publication Date Title
IL175953A (en) 3-cycloalkylaminopyrrolidine derivatives, pharmaceutically acceptable salts thereof and compositions comprising the same
TWI347199B (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
AU2003258848A1 (en) Hyaluronic acid derivatives and processes for preparing the same
PL369655A1 (en) Novel-beta-phenyl-alpha-oxysubstituted propionic derivatives, process for its preparation and their use in the preparation of pharmaceutically important compounds
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
AU2001230892A1 (en) Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same
WO2006015943A3 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
AU2003233010A1 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
IL165849A0 (en) Process for preparing pyrimidine derivatives novelpyrimidine derivatives and pharmaceutical composi tions containing the same
PL376154A1 (en) Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
AU2002232439A1 (en) Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU2002354054A1 (en) Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
AU2001262221A1 (en) Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
IL214387A (en) Tryptamine derivatives, method for their preparation and their use in the manufacture of pharmaceuticals and of tryptamine
AU2003231352A1 (en) Biocidal formulation and methods for the preparation thereof
AU6442900A (en) Aminocarbonyl-substituted benzimidazole derivatives, method for producing same and the use thereof as medicaments
AU2003219574A1 (en) Controlled release formulation comprising benzimidazole derivatives or pharmaceutically acceptable salts thereof with increased stability and method for preparing the same
AU2003292381A1 (en) Naphthyridine derivatives and their use as fungicides
AU2002339721A1 (en) Oxazolidinone derivatives, process for their preperation and their use as antimycobacterial agents
AU2002233407A1 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
AU2003224482A1 (en) Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
AU2003281698A1 (en) 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof
AU7268800A (en) Active agent preparation for veterinary use and method for the production thereof
AU2002313058A1 (en) Dihydroimidazo [5,1-A]-beta-carboline derivatives, method for preparing same and use thereof as medicine

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase